Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon in DSWPD subjects with CRY1Δ11 variant
NCT06701396Phase 3Recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in delayed sleep-wake phase disorder (DSPD) comparing Tasimelteon Sequence with Placebo Sequence (2 arms). Primary endpoint: Latency to Persistent Sleep. Started Oct 2024; status: recruiting.
02
Drugs
tasimelteon
03
Conditions
delayed sleep-wake phase disorder (DSPD)
Beyond the preview
Go deeper on NCT06701396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701396.